Background. Nocturnal rostral fluid shift has been suggested to be a risk factor for obstructive sleep apnea (OSA) in healthy subjects after lower body positive pressurization. It remains unclear whether this may apply to subjects with nephrotic lower limb edema and, if so, whether disease remission may reverse the accompanying OSA. Methods. Patients who presented with steroid-responsive primary nephrotic syndrome with lower limb edema as the predominant presenting clinical feature were recruited. They underwent one overnight polysomnography (PSG) before treatment and a repeat testing after achieving remission of the nephrotic edema. Results. Among 23 consecutive nephrotic subjects, 11 (48%) had polysomnographic evidence of sleep apnea [apnea-hypopnea index (AHI) ≥ 5] upon presentation. After steroid-based treatment, there was remission of proteinuria associated with complete disappearance of lower limb edema, significant reduction of body mass index, waist, hip and calf circumferences and total body water mainly in the extracellular compartment. Repeat PSG, performed 8.1 ± 2.6 months later, showed that the overall (N = 23) respiratory disturbance index (RDI) and AHI fell from 17.3 ± 5.0 to 8.7 ± 2.5 (P < 0.05) and from 16.3 ± 5.1 to 7.8 ± 2.3 (P = 0.057), respectively. Among the 11 subjects with sleep apnea detected at baseline, their AHI and RDI fell from 33.4 ± 7.8 to 15.0 ± 3.7 (P < 0.05) and from 34.8 ± 7.6 to 16.5 ± 4.0 (P < 0.05), respectively. There was also concomitant improvement in sleep efficiency, mean nocturnal oxygen saturation, shorter duration during sleep with oxygen saturation <95 and <90% and reduced desaturation index. There was also subjective improvement in self-reported daytime sleepiness. Conclusions. Nephrotic lower limb edema is associated with disturbed respiratory breathing and increased propensity to OSA, which was reversed upon remission of the nephrosis. This gathers a unifying concept for the role of nocturnal rostral fluid shift in the pathogenesis of OSA.
Introduction
Nocturnal rostral fluid displacement from the legs is increasingly recognized to play an important role in the pathogenesis of obstructive sleep apnea (OSA). In healthy non-obese subjects, application of lower limb positive pressure at 40 mmHg for up to 5 min increased neck circumference, airflow resistance at the pharynx, upper airway narrowing and collapsibility during recumbency [1] [2] [3] . More physiologically, an increase in neck circumference throughout the night has been shown to correlate with prolonged daytime sitting and the apnea-hypopnea index (AHI) in men undergoing polysomnography (PSG) for suspected OSA [4] . In diseased states such as heart failure, an inverse relationship was observed between overnight change in leg fluid volume and both the overnight change in neck circumference and the AHI in OSApredominant subjects [5] . In subjects with renal failure, more intense fluid removal during sleep using nocturnal cycler-assisted peritoneal dialysis relieved upper airway and tongue congestion and reduced AHI [6, 7] .
These studies suggest the importance of rostral fluid shift in the pathogenesis of OSA in healthy subjects and in patients who are prone to fluid overload. To strengthen this hypothesis, it is imperative to demonstrate whether alleviation of fluid accumulation, particularly in the lower limbs, may indeed attenuate the severity of or even reverse OSA. While it may not be possible to restore normal organ function without transplantation in heart failure or uremic subjects and thus eliminate excessive fluid accumulation entirely, patients with primary steroidresponsive nephrotic syndrome before and after corticosteroid therapy provide an ideal disease entity to address this research question. The present study, therefore, aims to track the changes, if any, in PSG parameters in subjects during the occurrence of predominantly lower limb edema and after its complete resolution.
Materials and methods

Patients
Between January 2008 and May 2011, we performed standard overnight PSG as soon as permissible, before the institution of corticosteroid treatment, on consecutive patients presenting with bilateral lower limb edema in whom a clinical or histologic diagnosis of steroid-responsive nephrotic syndrome was made. Inclusion criteria were as follows: (i) male or female aged 20-75 years; (ii) bilateral pitting lower limb edema (Grade 2 + or above on a scale [8] of 0-3 + ) as a presenting clinical feature; (iii) kidney biopsy diagnosis of minimal change disease or membranous nephropathy, de novo or relapsing; (iv) urinary protein excretion > 3.5 g/ day on at least two occasions and (v) serum albumin < 30 g/L. After the induction of disease remission, defined by the complete disappearance of leg edema and reduction of proteinuria to < 0.3 g/day (complete remission) or by > 50% from baseline ( partial remission), a second PSG was performed approximately 8-12 weeks after the withdrawal of corticosteroid. Exclusion criteria were as follows: (i) renal histology revealing a kidney disease that is unlikely to undergo rapid clinical remission with steroid therapy or other immunosuppressive agent, e.g. focal segmental sclerosis or amyloidosis; (ii) presence of secondary causes of nephrosis, e.g. diabetes, lupus or malignancy; (iii) presence of alternative non-renal causes of lower limb edema, e.g. cirrhosis, congestive heart failure; (iv) failure to induce disease remission, i.e. patients who had fulfilled the inclusion criteria and undergone the first PSG, but failed to achieve disease remission were excluded from the second PSG measurement and (v) patients with known sleep apnea or conditions predisposing to sleep apnea including congestive heart failure, cerebrovascular disease, chronic kidney disease or diabetes. The study flow diagram is illustrated in Figure 1 . The study protocol was reviewed and approved by the local Institutional Review Board and Clinical Research Ethics Committee from three regional renal centers, and all patients gave written informed consent to participate in the study.
Demographic characteristics, history and medication use were recorded before PSG and during follow-up. Just before PSG, subjective daytime sleepiness was also assessed using the Epworth Sleepiness Scale [9] . Circumference of the neck above the cricothyroid cartilage and of the thickest portion of both calves were tape-measured. Waist circumference was measured at a level halfway between the lower rib margin and the iliac crest.
Treatment of nephrotic syndrome
Treatment of nephrotic syndrome was commenced depending on the renal histological finding. For minimal change disease, standard therapy with prednisolone was started at 1 mg/kg/day (up to a maximum of 80 mg/day) and slowly tapered over a period of 4 months [10] . Addition of a second agent, such as calcineurin inhibitor or mycophenolate was permitted if clinically indicated. For idiopathic membranous nephropathy, we adopted a combination of prednisolone and cyclophosphamide or other agents based on our previous experience in Chinese subjects [11, 12] .
Polysomnography
Comprehensive overnight PSG was performed in hospital using Alice 3 or Alice 5 machine (Healthdyne, Atlanta, GA). Each subject underwent two PSGs: the first shortly after the diagnosis of nephrotic syndrome before the commencement of steroid therapy, and the second after disease remission when the patient was completely off corticosteroid therapy. Recordings included electroencephalogram (EEG), electrooculogram, submental electromyogram (EMG), bilateral anterior tibial EMG, electrocardiogram, chest and abdominal wall movement (respiratory effort) by inductance plethysmography, airflow by a nasal pressure transducer (PTAF 2; Pro-Tech, Woodinville, WA) and finger pulse oximetry. All variables were recorded continuously by a computerized data-acquisition system and stored on an optical disk for subsequent analyses.
All polysomnograms were scored manually by an independent expert in sleep medicine according to standard criteria [13] [14] [15] . Apnea was defined as the cessation of airflow for > 10 s, and hypopnea was defined as a reduction of airflow of ≥ 50% for > 10 s plus an oxygen desaturation of > 4%. The average number of episodes of apnea and hypopnea per hour of sleep (AHI) was calculated as the summary measurement of sleep-disordered breathing. Apnea was classified as central if there was no chest and abdominal movement or as obstructive if they moved paradoxically and as mixed if an initial absence of ventilatory effort was followed by an obstructive apnea pattern upon resumption of effort. The respiratory disturbance index (RDI) was the sum of AHI and respiratory effort-related arousal (RERA) events. An RERA event was defined as a sequence of breaths characterized by increasing respiratory effort leading to an arousal from sleep, but which did not meet the criteria for an apnea or hypopnea. To assess oxygen saturation during sleep, the following parameters were also manually scored: (i) mean nocturnal oxygen saturation (SaO 2 ) while in REM and non-REM sleep; (ii) minimal nocturnal SaO 2 and (iii) desaturation index, defined as the mean number of episodes of SaO 2 drop by > 4% per hour of sleep.
An arousal was scored if there was an abrupt shift in EEG frequency to α or θ of > 3 s or > 16 Hz, following at least 10 s of sleep, or if arising during rapid eye movement sleep, there must be a concomitant rise in EMG tone [15] . A respiratory arousal was defined as an arousal that occurred within 3 s after the termination of an episode of apnea or hypopnea.
Laboratory measurements
Complete blood count, standard renal function tests, estimated glomerular filtration rate, serum albumin, lipid profile, 24-h urine protein and spot urine protein-to-creatinine ratio were measured within 1 week prior to the first PSG and repeated at one to two monthly intervals and shortly before the second PSG.
Bioelectrical impedance analysis
Body water composition was measured prior to PSG in the evening using multi-frequency bioelectrical impedance analysis, and total body water (TBW), extracellular and intracellular water, and hydration fraction (TBW expressed as percentage of body weight) were computed according to previously described methods [6] .
Pulmonary mechanics
Standard spirometry was performed in accordance with the guidelines of the American Thoracic Society [16] on the night of PSG. Flow-volume measurements yielded the following parameters: forced vital capacity (FVC), forced expired volume in 1 s (FEV 1 ), peak expiratory flow rates at 50% (PEF 50% ) and 75% (PEF 75% ) of FVC and peak inspiratory flow rate at 50% (PIF 50% ) of FVC. Airflow limitation was also assessed using the peak flow ratios at mid-vital capacity (PIF/PEF 50% ). Pulmonary function results were expressed as measured and predicted values. Predicted vital capacity, inspiratory and expiratory flow rates and FEV 1 were based on gender, height and age.
Statistical analyses
Data were expressed as means ± SD unless otherwise specified. Statistical analyses were performed using SPSS for Windows software version 16.0 (Statistical Package for the Social Sciences Inc., Chicago, IL). Nonparametric paired-sample Wilcoxon signed-rank test was used to determine changes in sleep disturbance parameters, biochemical and anthropometric measurements and spirometry data before and after remission of nephrotic syndrome. P < 0.05 was considered significant. All probabilities were two tailed.
Results
Between 2008 and 2011, 38 patients who presented with bilateral lower limb edema and diagnosed clinically with primary nephrotic syndrome were recruited to undergo one PSG. Among them, 24 met all inclusion criteria and underwent the second PSG after a mean interval of 8.1 ± 2.6 months from disease onset (Figure 1 ). Upon analysis, one subject was found to have total sleep time < 4 h in the first PSG and was excluded due to inevitable inaccuracy with the manual PSG scoring. Therefore, 23 patients had two sets of evaluable PSGs, and their demographic data are shown in Table 1 . Eighteen (78.2%) and 5 (21.7%) patients underwent complete and partial remission of proteinuria, respectively, following treatment with steroidbased therapy for the nephrotic syndrome. All patients had steroid withdrawn for at least 8 weeks and complete disappearance of leg edema at the time of the second PSG. Their serum and urine biochemistries are shown in Table 2 . There was significant reduction of proteinuria and normalization of serum albumin levels. Anthropometric measurements revealed significant reduction of body mass index and waist, hip and calf circumferences after remission of the nephrosis. Multi-frequency bioelectrical impedance analysis showed a marked reduction of TBW and both extracellular and intracellular water. In particular, there was a 14.4 ± 12.3% reduction in hydration fraction or the percentage of body weight attributed to water only.
During the first PSG, 11 (48%) of the 23 subjects were detected to have sleep apnea (AHI > 5). The changes in sleep parameters associated with the disappearance of lower limb edema and reductions in body water contents are summarized in Table 3 . In particular, there was a significant reduction in the respiratory disturbance index (17.3 ± 5.0 versus 8.7 ± 2.5, P < 0.05) with remission of the nephrotic syndrome. In addition, there was a tendency for a fall in AHI (16.3 ± 5.1 versus 7.8 ± 2.3, P = 0.057) after disease remission, and this was attributed mostly to reductions in the obstructive component (14.4 ± 3.9 versus 7.7 ± 2.3, P = 0.051). There was also improvement in sleep efficiency (P = 0.04), mean oxygen saturation (P = 0.029), shorter duration with oxygen saturation < 95% (P = 0.044) and < 90% (P = 0.046), and lower desaturation index (P = 0.023) during sleep. When subjects with baseline AHI ≥ 5 (N = 11) and remission of nephrotic syndrome were analyzed separately, the mean AHI fell from 33.4 ± 7.8 at baseline to 15.0 ± 3.7 after disease remission (P = 0.045), and the corresponding obstructive AHIs were 29.6 ± 5.2 and 15.2 ± 3.6, respectively (P = 0.038). The corresponding RDI also decreased from 34.8 ± 7.6 to 16.5 ± 4.0 (P = 0.035). The individual changes in AHI and RDI values during severe nephrosis with leg edema and during disease remission without leg edema are shown in Figures 2 and 3 , respectively. In addition, there was subjective improvement in self-reported daytime sleepiness as measured by the Epworth Sleepiness Scale (P = 0.009, Table 3 ).
Pulmonary function tests using standard spirometry showed no difference in any of the spirometric parameters measured during nephrosis and remission (Table 4) .
Discussion
OSA is an important cause of cardiovascular morbidity in the general population [18] and dialysis patients [19] . However, its pathogenesis is not fully understood. Nocturnal rostral shift of fluid from the lower extremities to the upper body causing airway obstruction during sleep has been suggested to be one of the mechanisms as demonstrated artificially via application of lower body positive pressure in healthy subjects [1] . Here, we investigated whether this theory may indeed be true in real patients with genuine lower limb edema as occurs with the nephrotic syndrome. We observed that the prevalence of sleep apnea (AHI > 5) in nephrotic subjects was 48%, as opposed to only 2-4% in the community [20, 21] , suggesting that nephrotic edema may be a risk factor for OSA. This is further supported by the fact that the predominant form of apnea is obstructive in nature. We believe that this increase in prevalence is genuine as we have excluded subjects with known sleep apnea and other conditions that predispose to sleep apnea in our cohort.
Interestingly, this prevalence is somewhat below that observed in uremic subjects ( > 50%) [6, 22] in whom sleep apnea may be attributed to a combination of both fluid retention and accumulation of uremic wastes [7] . Remission of nephrotic syndrome, characterized by the complete or partial amelioration of proteinuria and normalization of serum albumin and lipid abnormalities, was associated with marked reduction in body mass index and TBW, mainly in the extracellular compartment as this component of body water decreased by 22.2%. The overall hydration fraction ( percentage of body weight attributable to water only) decreased by 14.4%. Clinically, this translated into disappearance of lower body edema as reflected more objectively by significant reductions in waist, hip and calf circumferences, together with a modest but significant lowering of both systolic and diastolic blood pressures. This shedding of lower body fluid was associated with improvements in overall sleep efficiency and nocturnal oxygen saturation during sleep as evidenced by a significant increase in mean nocturnal SaO 2 and shortening of duration with SaO 2 < 95 and 90%, culminating in a significant reduction in the overall desaturation index and albeit not reaching statistical significance, snoring and arousal indices. Neck circumference, however, was not significantly reduced. This is not surprising as volumetric changes only lead to subtle changes in airway dimensions which, although enough to cause OSA, were unlikely to be sufficient to give rise to a tangible reduction in tape-measured neck circumference, as we recently observed in dialysis subjects who were switched from conventional continuous ambulatory peritoneal dialysis to nocturnal peritoneal dialysis, a more intensive form of fluid-removing therapy for end-stage renal disease [7] . More importantly, the remission of nephrosis and the accompanying edematous state was associated with significant improvements in daytime sleepiness (as reflected by the Epworth questionnaire) and in the major sleep apnea indices, namely the RDI and AHI. The reductions in these indices were more pronounced among subjects with baseline sleep apnea (AHI ≥ 5), suggesting that nephrotic edema indeed plays a role in the pathogenesis of OSA. Although our results are not as robust as those among healthy subjects who developed increased pharyngeal resistance and airway collapsibility after lower limb pressurization [1] [2] [3] , it must be emphasized that in these subjects lower limb fluid was forced into the upper body including the airway, whereas in our nephrotic cohort, edema was more generalized and fluid redistribution on lying down would not be as rostrally directed without leg pressurization.
In terms of lung function, there was hardly any difference in respiratory mechanics after resolution of nephrotic edema. In particular, the indices of airflow velocity and airway obstruction, namely FEV 1 , FEV 1 /FVC and PIF/ PEF 50% , remained unchanged. These findings concur with our recent study [6] in uremic subjects with different fluid status and with other reports showing that sleep apnea is unrelated to pulmonary function measurements [23] and that flow-volume curve indices have no value in predicting sleep apnea [24] . Nevertheless, the standard respiratory mechanics measurements performed here with the patients upright and awake may not reflect the real status during sleep. There are certain limitations in our study. First, the study population is small. This is due partly to the low incidence rate of primary steroid-responsive nephrotic syndrome in our study in which three regional renal centers participated and partly to our very stringent selection criteria to focus on a very specific group of patients in order to reduce bias arising from heterogenous disease entities. In addition, the discomfort induced by the PSG measurement itself has deterred some eligible subjects from undergoing the repeat measurement. Second, the use of corticosteroid-based therapy may be a risk factor for sleep apnea due to changes in regional adiposity induced by steroid [25] . To this end, we allowed a washout period of at least 8 weeks after complete steroid withdrawal so as to minimize any residual steroid effect to be carried over to the second PSG. Finally, there is the lack of a parallel group of patients with repeated sleep studies during the nephrotic phase and/or after relapse which might otherwise further strengthen our observation.
In conclusion, we have shown for the first time that disturbed respiratory breathing is evidently prevalent among patients with nephrotic syndrome. We have also provided evidence to strengthen a unifying concept that nocturnal rostral fluid shift is associated with nocturnal desaturation and increased propensity to OSA for the first time in patients with lower limb edema due to the nephrotic syndrome in addition to those patients with heart failure and uremia [5] . Such a finding has clinical implications as disturbed respiratory breathing may contribute to the heightened cardiovascular and thrombotic risks associated with this condition. Our results are in agreement with those by the Toronto group [1] [2] [3] whose seminal reports on the role of displacing lower body fluid in the pathogenesis of sleep apnea paved the way for further investigations in the field. Our approach took one step further in that alleviation of excessive lower body fluid reversed several parameters of sleep-disordered breathing and lent further support to the pivotal role of fluid overload in the pathogenesis of OSA.
Introduction
The incidence of congestive heart failure (CHF) is still increasing. Continuing improvement of cardiac care has resulted in more people surviving acute cardiac diseases and consequently living longer to eventually develop heart failure. Treatment of hypervolaemic patients with CHF complicated by progressive and permanent chronic renal insufficiency, also known as the cardiorenal syndrome (CRS) Type 2, is notoriously difficult [1] . Patients may develop diuretic resistance leading to recurrent episodes of pulmonary congestion and oedema [2] [3] [4] . In patients with acute decompensated heart failure, continuous ultrafiltration resulted in a reduction in rehospitalization during a 90-day follow-up period [5] . However, this treatment modality is less suitable for chronic treatment of diuretic resistance, such as may occur during CRS Type 2.
Peritoneal dialysis (PD) has main characteristics of gradual fluid removal and extra sodium loss and offers potential advantages in patients with CRS Type 2, even when not complicated by severe renal failure [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Several small studies have shown that extracorporeal treatment may be useful in the treatment of CRS Type 2 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . In the majority of these patients, an improvement of functional status [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] 25] and a reduction in hospitalization were observed compared to historical data [18] [19] [20] [21] [22] [23] [24] [25] . Recently, we performed a retrospective analysis in patients with CRS Type 2 and treated with PD [26] . Survival time after starting PD was highly variable and the
